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ABSTRACT 
Background: The optimal management approach to pancreatic serous cystic neoplasms 
(SCNs) is still evolving.  
Methods: Consecutive patients with SCN managed at the Liverpool Pancreas Cancer Centre 
between 2000 and 2013 were retrospectively reviewed.  
Results: There were 64 patients, 39 women (60.9%) and 25 men (39.1%). Forty-seven patients 
(73.4%) had surgical removal and 17 (26.6%) were observed. The possibility of a non-SCN 
malignancy was the predominant indication for resection in 27 (57.4%) patients. Post-operative 
morbidity occurred in 26 (55.3%) patients with two (4.3%) deaths. An increased risk of 
resection was associated with patient’s age (p=0.011), diagnosis before 2009 (p<0.001), pain 
(p=0.043), possibility of cancer (p=0.009) and a solid SCN component on imaging (p=0.002). 
Independent factors associated with resection were a diagnosis before 2009 (p=0.005) and a 
solid SCN component (p<0.001). Independent factors associated with shorter time to surgical 
resection were persistent pain (p=0.003) and a solid SCN component (p=0.007). 
Discussion: There was a reduction in the proportion of resections with the application of an 
observe-only policy for asymptomatic patients with more definite features of SCN. Improved 
criteria are still required in the remainder of patients with uncertain features of SCN in 
deciding for intervention or surveillance.  
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INTRODUCTION 
 
Pancreatic serous cystic neoplasms (SCNs) comprise 10–15% of pancreatic cystic neoplasms 
and 1–2% of all pancreatic neoplasms 1. SCNs along with other pancreatic cystic neoplasms 
including mucinous cystic tumours, cystic pancreatic endocrine neoplasms, solid 
pseudopapillary neoplasms and intraductal papillary mucinous neoplasms (IPMNs), are 
increasingly identified as a consequence of the wider application of cross sectional imaging 
2-4
. 
They are either discovered incidentally
 2,5
 or are associated with non-specific abdominal 
symptoms due to local expansion 
3,6
. In contrast to mucin producing cystic tumours, SCNs are 
almost always benign with only a small number of primary serous cystadenocarcinomas 
reported 
7-12
.  
Improvements in pancreatectomy with lower associated mortality have increased our 
confidence in performing pancreatic resections for ambiguous pancreatic lesions
13,14
, however 
the associated morbidity remains high even in specialized centres 
15
. The decision to operate on 
or observe patients with SCNs, or with equivocal imaging characteristics resembling SCNs, 
remains very challenging 
3,16
.  
 
This study aims to contribute to the improved management of SCNs, by identifying factors that 
influence decision making for resection versus surveillance. 
 
 
METHODS 
 
Patients with a final diagnosis of SCN were identified from the databases of the Multi-
Disciplinary Team of the Liverpool Supra-Regional Pancreas Cancer Centre and the National 
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Institutes of Health Research (NIHR) Pancreatic Biomedical Research Unit (PBRU) of the 
Royal Liverpool University Hospital. The diagnosis of SCN was based on radiology 
17
 and/or 
pathology following surgical resection 
18
.  The data refining and analysis was undertaken 
retrospectively and covered the period from the 1
st
 January 2000 until 31
st
 December 2013. 
Because of incomplete data for some fields the denominator is given when less than the total 
number of expected observations. 
 
The Multi-Disciplinary Team included specialist pancreatic surgeons, gastroenterologists, 
medical oncologists, radiologists and pathologists. All patients were reviewed at the Multi-
Disciplinary Team weekly meeting. The diagnosis or differential diagnosis of SCN and the 
decision to operate or undertake further imaging was made collectively at the meeting and 
recorded at the time. From 2009 in addition to cross sectional imaging, endoluminal ultrasound 
(EUS) with fine needle aspiration was used to assist decision making according to the 
Liverpool pancreatic cyst protocol (which is being prospectively evaluated). In addition to 
worrying radiological features, the indications for intervention for any type of pancreatic cyst 
are suspicious cytology, cyst fluid CA 19.9 > 50,000 KU/L and or cyst fluid CEA>450 μg/L 19-
21
. 
 
The macroscopic imaging diagnosis of SCN was categorised as microcystic (honeycomb) type 
(cysts < 1cm), macrocystic/oligocystic type (cysts > 1 cm), mixed microcystic and macrocystic 
type, and solid type 
22
. The diagnosis of SCN was histologically confirmed in all patients who 
underwent a resection. Patient characteristics including demographics, disease presentation, 
comorbid conditions, radiological and endoscopic evaluation and relevant surgical treatment 
with pathology, morbidity, mortality, postoperative recovery and length of hospital stay were 
obtained. Follow up data were collected from Multi-Disciplinary Team proformas, hospital 
admissions and clinic visits. 
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Statistical Analysis 
Continuous variables were expressed as median and interquartile range (IQR) and were 
compared using Mood’s median test; categorical variables were compared using Fisher’s exact 
probability test (two-tailed). Median resection free period and corresponding episode free 
periods were calculated by the Kaplan-Meier method and the asymptotic log rank test was used 
to evaluate significant differences. Univariate logistic regression was used to identify factors 
predictive of a pancreatic resection. Subsequent multivariate logistic regression was used to 
assess independent predictors of pancreatic resection vs. observation for SCN patients. We 
used a stepwise model selection process based on the Akaike’s Information Criterion and the 
Le Cessie – Van Houwelingen test to assess the goodness of fit of the optimal predictive 
model. Finally, a Cox proportional hazards model was used to assess the effect of various 
covariates on the resection free period and Scaled Shoenfeld residuals were used to evaluate 
the proportional hazards assumption. The significance level for all the tests was set to α = 0.05. 
Statistical analyses were performed using R version 3.0.2 (R Development Core Team, 2013) 
23
. 
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RESULTS 
 
Sixty four patients with SCN were identified spanning the 14 year time period consisting of 39 
(60.9%) women and 25 (39.1%) men, with a median (IQR) age of 70.5 (59-77) years (Table1). 
There were smoking and alcohol data on 39 patients, of whom 12 (30.8%) were smokers and 
19 (48.7%) had excess alcohol intake. Cystic pancreatic lesions were discovered incidentally 
during work-up for another condition in 31 (55.4%) of 56 patients. Documented presenting 
symptoms included pain in 15 (27.8%) of 54 patients, diarrhoea in 5 (10.2%) of 49 patients and 
jaundice in 3 (5.6%) of 54 patients. Diabetes was present at the time of referral in 5 (10.4%) of 
48 patients while a single patient (2%) of 49 patients had exocrine insufficiency. Forty-seven 
patients (73.4%) underwent a resection and 17 (26.6%) were followed up. The indications are 
shown in Figure 1 (CONSORT).    
 
Imaging 
Computed tomography (CT) was the initial diagnostic modality in 50 (78.1%) patients 
followed by magnetic resonance imaging (MRI) in seven (10.9%), abdominal ultrasound (US) 
in five (7.8%) and EUS in two (3.1%) patients (Table 1). CT continued to be applied as a 
monitoring tool in 32 (64%) of 50 patients. In the remaining 18 patients, additional imaging 
modalities during the follow up period included EUS in nine (14.1%), MRI in two (3.1%), 
MRI and EUS in four (6.3%), laparoscopic ultrasound in two (3.1%) and positron emission 
tomography (PET) CT in another (1.6%). The initial diagnosis of SCN in 14 (21.9%) patients 
did not involve CT, of whom six had an MRI, four had an EUS, three had a transabdominal US 
and one had a combination of EUS and MRI.   
The use of EUS for surveillance was not statistically significant either before (n=6, 23.1%) or 
after (n=12, 31.6%) 2009 (p=0.575).  EUS was more frequently performed in patients with 
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lesions measuring ≤ 30mm in diameter (N=14, 45.2% vs. N=2 6.7%, p=0.001) but was not 
associated with subsequent resection (12/18, 66.7% vs 35/46, 76.1%, p=0.533).  
 
On imaging a solid element was present in 25 (46.3%) of 54 cystic lesions, calcifications in 13 
(23.2%) of 56 lesions, eight (14.5%) of 55 cysts were hypervascular, there was a dilated 
(>6mm) main pancreatic duct in nine (16.4%) of 55 patients and there was vascular 
compression by the cyst in six (10.9%) of 55 patients. 
 
Twenty-six (40.6%) SCNs were located in the head of pancreas, 16 (25%) in the pancreatic 
tail, 11 (17.2%) in the pancreatic body, six (9.4%) in the body and tail of pancreas, one (1.6%) 
in the pancreatic head and neck junction, one (1.6%) each in the pancreatic neck and body 
junction, the pancreatic neck and the uncinate process and one other replaced the entire 
pancreas.  The median (IQR) cyst diameter was 3 (2.1-5.7) cm. Thirty-two (51.6%) of 62 cysts 
were microcystic, 26 (41.9%) were macrocystic, three (4.8%) were solid type and one (1.6%) 
was mixed type on imaging. 
 
Cyst analysis  
Two patients (both with negative cytology) had cyst CA19-9 and CEA levels of 32,730 KU/L 
and 1,372 μg/L and 11 KU/L and 5,247μg/L respectively and went on to have a resection, the 
first a pylorus preserving partial pancreato-duodenectomy (PPPD) and the other a radical left 
pancreatectomy. Both had a macrocystic SCN on histology. 
 
Three other patients (all with negative cytology) had cyst CA19-9 and CEA levels of 1,513 
KU/L and 42μg/L, 61 KU/L and <1μg/L and 68,525 KU/L and 431 μg/L respectively and one 
had levels unreported; all four remain under surveillance. 
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Surgical procedures 
The concern for the possibility of a non-SCN malignant cyst, the presence of a solid cyst 
component, relatively younger age and pain were all significantly different between the 
resected and non-resected groups (Table 1). In addition all but one (96.1%) of 26 patients seen 
during 2000-2009 had resection compared to 22 (57.9%) of 38 patients seen during 2009-2013 
(p<0.001). The differences in patient characteristics seen before and after 2009 are depicted in 
Table 2.   
 
The operations comprised a PPPD in 20 (42.6%) patients, a radical left pancreatectomy (with 
splenectomy) in 14 (29.8%) patients, a spleen preserving left pancreatectomy in eight (17%) 
patients, a total pancreatectomy and splenectomy in three (6.4%) patients, a duodenum 
preserving total pancreatectomy in a single (2.1%) patient and a local excision in the remaining 
one (2.1%) patient. Combined procedures for simultaneous cancers were performed in three 
patients: an oesophagectomy for oesophageal cancer, a right hemicolectomy for colon cancer 
and a left nephrectomy for renal cell carcinoma. Post-operative morbidity occurred in 26 
(55.3%) patients including two (4.3%) deaths, both in men who had had a PPPD for concerns 
of non-SCN malignancy.  One was 53 years old with portal hypertension due to Child’s B liver 
disease with a 55 mm cyst with calcification, a dilated main pancreatic duct and compression 
of the hepatic portal vein with persistent symptoms who developed post-operative liver failure. 
The other was 68 years old with a large cyst in the head of pancreas, who had a major 
postoperative bleed which could not be controlled with embolization. The median (IQR) total 
hospitalization was 20 (12- 28.5) days.   
 
Pathology of resected cysts 
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On histology all of the lesions were completely excised. There were 29 (61.7%) microcystic 
SCNs, eight of these with a stellate scar, a classic feature of a microcystic SCN. 
 
There were 17 (36.2%) patients with macrocystic/oligocystic SCNs and one (2.1%) had a solid 
type SCN. Low grade pancreatic neuroendocrine tumours (PNETs) all with a Ki67 <1%, were 
identified incidentally on histology in eight of the 17 macrocystic/oligocystic SCN specimens, 
including in one patient with von Hippel Lindau disease. Another patient with a 
macrocystic/oligocystic SCN also had a splenic marginal zone lymphoma in the specimen. 
 
The median number (IQR) of lymph nodes removed was 10.5 (3-15) and none had any micro- 
metastases. Pancreatic intraepithelial neoplasia (PanIN lesions type 1 were identified in 22 
(53.7%) of 41 pancreata and one (2.4%) specimen had a PanIN type 2. Pancreatic fibrosis was 
present in 24 (58.5%) of 41 specimens, which was localized around the SCN in most of the 
patients.  
 
Independent predictors of pancreatic resection 
The factors associated with a significant decrease in SCN resection after 2009 compared with 
previously were further analysed (Table 2). The concern for the possibility of cancer in a non-
SCN lesion (based on imaging) as a reason for resection includes a substantive subjective 
element and was therefore removed from the subsequent regression analysis. This showed that 
the presence of a SCN solid component as well as diagnosis before 2009, independently 
predicted the decision to perform a pancreatic resection for SCNs (Table 3a).  
 
The median and 95% confidence interval (CI) resection free time was 3.7 (3.1 -9.1) months. 
The median (IQR) follow up period was 3.1 (1.9-4.8) months for SCN patients undergoing 
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resection and 8.3 (7.0-19.2) months for patients under surveillance. Factors associated with a 
significantly decreased resection free period were the presence of a SCN solid component on 
imaging (p=0.002; Figure 2a), a SCN diameter ≤ 30 mm (p=0.032; Figure 2b), concern for a 
non-SCN malignancy (p=0.035; Figure 2c) and persistent pain (p=0.024; Figure 2d). After 
excluding the cancer fear factor, the Cox proportional hazards model identified persistent pain 
and a solid SCN component on imaging as being independently associated with shorter time to 
surgical resection (Table 3b). 
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DISCUSSION 
Currently there is no standard management for SCNs, with preferences ranging from routine 
surveillance of all patientss to resection for all SCNs 
4,8,9,11,12,15,17
. The risk for progression of 
an SCN to a serous cystadenocarcinoma is extremely low and previous estimates of up to 3% 
8 
are now known to be excessive with fewer than 25 cases reported in the world literature
 18
. 
Because there are close similarities on imaging between macrocystic/oligocystic SCNs and 
mucinous cystic neoplasms and IPMNs it is difficult to differentiate between these lesions prior 
to committing to expectant management. This difficulty partly accounts for variances in 
proposed management options [Table 4].  
 
In the present study patients with persistent pain and a solid cyst component, indicating 
concerns of a non-SCN malignant lesion, independently predicted an earlier operation. Patients 
with SCN diagnosed before 2009 were more frequently operated upon as compared to being 
followed up with repeat imaging. This can be attributed to changing referral patterns as well as 
conceptual changes seeking to reduce intervention rates. There were more patients presenting 
with pain before 2009 and greater use of cross sectional imaging after 2009. A solid component 
in the SCN and diagnosis or referral before 2009, were independently associated with a 
decision to perform a pancreatic resection.  
 
A recent joint study from the multi-disciplinary pancreas cancer units at the Universities of 
Harvard and New York and the Mayo Clinic, Rochester, Minnesota proposed annual imaging 
for asymptomatic SCNs and those <4 cm 
17
.  For asymptomatic thin-walled unilocular cystic 
lesions <3cm they proposed CT or MRI imaging at 6 and 12 months. If there were more 
complex features or growth rates > 1 cm per year they recommended more intense follow up or 
resection. It was proposed that symptomatic cystic lesions, neoplasms with high malignant 
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potential and lesions >3 cm should be referred for surgical evaluation 
17
. 
 
In practice such 
guidelines are difficult to follow as there is no relationship between the diameter of SCNs and 
the risk of malignancy 
12
. Moreover if there is a suspected high risk of malignancy then the 
observed pancreas lesion on imaging is not a SCN. Serous cystadenocarcinoma cannot be 
defined by the histological appearances of the pancreatic SCN but rather by its behaviour in the 
development of metastases to the lymph nodes, liver, peritoneum and elsewhere 
18,25
.
  
 
The largest single centre SCN series of 217 patients from the Johns Hopkins Medical 
Institutions in Baltimore, Maryland, reported that preoperative CT was suggestive of SCN 
diagnosis in less than a quarter of patients. They proposed that small neoplasms in the body 
and tail of the pancreas with pathognomonic SCN features on cross-sectional abdominal 
imaging (comprising a central stellate scar and/or with multiple microcysts) could be managed 
conservatively 
25
.
 
Thus the key issue remains an accurate and certain diagnosis of SCN 
especially in the case of non microcystic SCNs, which in the current series comprised 32 (50%) 
of the 64 patients. 
 
The Verona group were able to prospectively monitor 145 patients with SCN of whom only 23 
(15.9%) underwent a pancreatic resection during surveillance 
12
.
 
The study indicated that in 
their particular series significant growth of the SCN was unlikely <7 years from baseline and 
that macrocystic SCNs, a history of non-pancreatic malignancies and increased age were all 
predictors of SCN growth. The Verona study concluded that asymptomatic or minimally 
symptomatic SCNs >4 cm could undergo surveillance of no less than two yearly intervals 
12
.
 
The diagnostic accuracy of CT for SCN is around 20-23% rate 
25,27,28
 so additional cross 
sectional imaging with MRI and EUS especially for cystic lesions measuring ≤ 30mm with a 
suspicious solid component might improve decision making 
29
. The morbidity of pancreatic 
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resection remains substantial, and although in most series of SCN the mortality from pancreatic 
resection is low
15,30
, every effort is required to avoid mortality from benign conditions. 
Recently improved surgical results have been shown in a series of 53 patients who underwent 
enucleation for localised pancreatic lesions (including neoplastic cysts) compared to a case 
controlled resection series 
31
.
 
This is an important positive development and adds another layer 
in what is becoming a complex management algorithm for this group of patients. 
 
More accurate means of discriminating SCN from other potentially malignant pancreatic cystic 
neoplasms is needed with considerable interest in cyst fluid tumour markers 
32,33
. Presently we 
are evaluating cyst levels of CA-199 and CEA but the full contribution to clinical decision 
making is not yet established 
19-21
. The combination of GNAS and KRAS testing appears 
accurate for diagnosing IPMNs but not for distinguishing mucinous cysts from SCNs and other 
pancreatic cysts 
34
. Cyst fluid may be used to detect high-risk IPMNs employing the Das-1 
monoclonal antibody raised against a reactive premalignant colonic epithelial phenotype 
35
. A 
nine miRNA panel may also be able to distinguish high-grade IPMNs, PNETs and 
pseudopapillary neoplasms from low-grade IPMNs and SCNs 
36
. Most recently cyst fluid 
VEGF-A levels were found to be significantly upregulated in test series of SCNs compared 
with other pancreatic cysts and with a cut-off of 8,500pg/mL, VEGF-A had a 100% sensitivity 
and 97% specificity as an SCN biomarker 
37
. Whilst all of these pancreatic cyst fluid 
biomarkers look promising they are still in the evaluation stage and need to be validated in 
independent cohort.  EUS employing high-resolution optical imaging also offers considerable 
opportunities for differentiating serous from mucinous and other cystic neoplasms, which  
includes both confocal endomicroscopy 
38
 and optical coherence tomography 
39
 but further 
prospective studies are required to determine the most appropriate diagnostic clinical context .
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The present study supports the relatively conservative approach proposed by the Verona group 
of surveillance in asymptomatic patients with definite features of SCN 
12
.  Nevertheless, 
improved criteria are still required in the remainder of patients with uncertain features of SCN 
in deciding whether to continue surveillance or proceed to resection. 
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Table 1. Comparison between Resection Group and Observation Group of patients with SCN. 
 
Characteristic 
Resection 
Group (n=47) 
Observation 
Group (n=17) 
Numbe
rmissin
g
a 
Relative Risk p-value
b
 
      
Female 27 (57.4%) 12 (70.6%) 0 0.87 0.397 
      
Age (years)
c 
68 (58.5, 74) 77 (69, 82) 0 - 0.011
d 
 
     
Year of Diagnosis      
2000 – 2009 (N=26) 25 (53.2%) 1 (5.9%) 
0 - <0.001  (96.1%in period) (3.9% in period) 
2009 – 2013 (N=38) 22 (46.8%) 16 (94.1%) 
 (57.9% in period) (42.1%in period)    
 
     
Diagnostic Imaging      
CT
 
35 (74.5%) 15 (88.2%) 
0 - 0.550 
MRI 5 (10.6%) 2 (11.8%) 
EUS 2 (4.3%) 0 (0%) 
US 5 (10.6%) 0 (0%) 
      
Pain 14 (35.9%) 1 (6.7%) 8, 2 1.46 0.043 
      
Jaundice 3 (7.7%) 0 (0%) 8, 2 1.42 0.552 
      
Diabetes 5 (12.8%) 0 (0%) 8, 8 1.27 0.568 
      
Incidental discovery 21 (52.5%) 10 (62.5%) 7, 1 0.89 0.563 
      
Possibility of cancer 27 (57.4%) 3 (17.6%) 0 1.53 0.009 
      
EUS for follow up 12 (25.5%) 6 (35.3%) 0 0.88 0.533 
      
Head and Neck SCN 23 (48.9%) 6 (35.3%) 0 1.16 0.402 
 
     
Macroscopic type
e      
Macrocystic/Oligocysti
c
 
18 (38.3%) 8 (47.1%) 
0 - 0.786 Microcystic 24 (51.1%) 8 (47.1%) 
Solid 3 (6.4%) 0 (0%) 
Mixed 1 (2.1%) 0 (0%) 
Unclassified 1 (2.1%) 1 (5.9%)    
 
     
Maximum diameter      
SCN ≤ 30mm 25 (55.6%) 6 (37.5%) 2, 1 1.21 0.255 
      
Solid Component 23 (60.5%) 2 (12.5%) 9, 1 1.78 0.002 
      
Calcifications 9 (23.1%) 4 (23.5%) 8, 0 0.99 1.000 
      
Hypervascularity 7 (17.9%) 1 (6.3%) 8, 1 1.29 0.414 
      
Pancreatic Duct > 5mm
 
6 (15.8%) 3 (17.6%) 9, 0 0.96 1.000 
      
Vascular compromise 4 (10.5%) 2 (11.8%) 9, 0 0.96 1.000 
 
a. Resected group, Observation group  
b. Fisher’s exact test  
c. Median (IQR)  
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Table 2. Clinical characteristics according to the year of diagnosis in patients with SCN. 
 
Characteristic 
Before 2009   
(n=26) 
After 2009      
(n=38) 
Number 
missing
a p-value
b
 
     Female 17 (65.4%) 22 (57.9%) 0 0.609 
     
Age (years)
c 
67 (54.3, 74) 72.5 (62, 78) 0 0.884
d 
     
Diagnostic Imaging     
CT 17 (65.5%) 33 (86.8%) 
0 0.022 
MRI 3 (11.5%) 4 (10.5%) 
EUS 1 (3.8%) 1 (2.7%) 
US 5 (19.2%) 0 (0%) 
     
Pain 10 (58.8%) 5 (13.5%) 9, 1 0.001 
     
Jaundice 2 (11.8%) 1 (2.7%) 9, 1 0.230 
     
Diabetes 1 (5.9%) 4 (12.9%) 9, 7 0.643 
     
Incidental discovery 7 (38.9%) 24 (63.2%) 8, 0 0.149 
     
EUS for follow up 6 (23.1%) 12 (31.6%) 0 0.575 
     
Macroscopic type
e     
Macrocystic/ Oligocystic
 
9 (35%) 17 (44.7%) 
0 0.668 
Microcystic 14 (54%) 18 (47.4%) 
Solid 1 (4%) 2 (5.3%) 
Mixed 1 (4%) 0 (0%) 
Unclassified 1 (4%) 1 (2.6%)   
     
Maximum diameter     
SCN ≤ 30mm 11 (45.8%) 20 (54.1%) 2, 1 0.605 
     
Solid Component 7 (38.9%) 18 (50%) 8, 2 0.565 
     
Calcifications 2 (11.1%) 11 (28.9%) 8, 0 0.186 
     
Hypervascularity 2 (11.1%) 6 (16.2%) 8, 1 1.000 
     
Pancreatic Duct > 5mm
 
4 (23.5%) 5 (13.2%) 9, 0 0.435 
     
Vascular compromise 3 (16.7%) 3 (8.1%) 8, 1 0.381 
 
     
  Resection group   
     
Resection criteria     
Possibility of non-SCN cancer
 
11 (44%) 16 (72.7%) 
0 0.026 Symptoms 8 (32%) 6 (27.3%) 
Increasing cyst size 6 (24%) 0 (0%) 
     
Associated malignancy 4 (16%) 5 (23.8%) 0, 1 0.711 
     
     a. Resected group, Observation group   
b. Fisher’s exact test     
c. Median (IQR)     
d. Mood’s two-sample median test: Z= 0.146 
 
 
 
 
 
e. Based on imaging. 
  
 e. Based on imaging. 
d. Mood’s two-sample median test: Z= -2.546 
e. Based on imaging. 
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Table 3. Multivariate analyses in patients with SCN: logistic regression model evaluating 
predictors of pancreatic resection (Table 3a); Cox proportional hazards model analysing factors 
independently associated with shorter time to surgical resection (Table 3b). 
 
Table 3a. 
Parameter* 
log(OR) 
estimate 
95% CI p-value 
Goodness of fit test 
(p-value) 
Predicted 
Probabilities 
Intercept -0.964 -2.099, 0.007 0.066 
0.855* 
27% 27% 
Before 2009 3.302 1.372, 6.336 0.005 91% - 
Solid 
Component 
3.062 1.452, 5.138 <0.001 99% 89% 
Pain Excluded due to non-significant contribution in model’s fit as assessed by 
Akaike’s Information Criterion. Age 
 
 
Table 3b.  
Parameter 
Hazard 
Ratio 
95% CI 
Wald test 
statistic 
p-value 
Solid Component* 3.05 1.46, 6.37 2.966 0.003 
Pain 2.57 1.29, 5.12 2.688 0.007 
PSC >30 mm 
Excluded as having no significant effect on resection free 
survival after adjusting for “Solid Component” and “Pain” 
status. 
*Proportional Hazards assumptions evaluated using scaled Schoenfeld residuals. 
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Table 4. Larger published series of patients with SCNs undergoing pancreatic resection and/or 
observation. 
 
Author Year Number 
of 
Patients  
Patients 
Resected 
Number (%) 
Patients 
Observed 
Number (%) 
Surveillance Time Patients with 
Symptoms 
Number (%) 
Microcystic 
SCNs                  
Number (%) 
Solid 
Component 
Number (%) 
Cyst 
Diameter 
(cm) 
Metastatic 
SCNs No (%) 
PNETs
a
 
Number 
(%) 
Tseng et al.
24
  2005 106 86 (81.1%) NA
a
 NA 56 (53%) 7 (7%) NR
c
 Mean=4.9 0 (0%) 1 (1%) 
Galanis et al. 
15
 2007 158 158 (100%)  NA NA 101 (64%) NR NR Mean=5.1 2 (1.3%) NR 
Khashab et al. 
25
 2011 257 257 (100%) NA NA 152 (59%) NR NR Mean=4.9 2 (0,8%) NR 
Kimura et al. 
22
 2012 172 82 (47.7%) 90 (52.3%)  Mean=4.5 yrs 34 (20%) 69 (39%) NR Mean=4.1 3 (3.7%) 0 (0%) 
Malleo et al. 
12
 2012 145 23 (15.9%) 122 (84.1%)  Mean=7 yrs 27 (18.6%) 21 (14.5%) NR Mean=2.9 0 (0%) NR 
El-Hayek et al.
26
 2013 219 25 (11.4%) 194 (88.6%) Median=3.2 years 49 (24%) NR NR Median=2 0 (0%) NR 
Gomatos et al. 2013 64 47 (73.4%) 17 (26.6%) Median=3.4 months
 
25 (44.6%) 32 (50.0%) 25 (46.3%) Median=3 0 (0%) 8 (17.4%) 
 
a. Pancreatic neuroendocrine tumours 
b. Not Applicable 
c. Not Reported 
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LEGENDS FOR FIGURES  
Figure 1. CONSORT diagram describing outcome of the study. 
Figure 2. Factors associated with a significantly decreased resection free period due to: the 
presence of a SCN solid component on imaging (Figure 2a);  SCN diameter ≤ 30 mm (Figure 
2b); concern for a non-SCN malignancy (Figure 2c); and persistent pain (Figure 2d).  
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